204 related articles for article (PubMed ID: 20644084)
1. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.
Gutierrez A; Dahlberg SE; Neuberg DS; Zhang J; Grebliunaite R; Sanda T; Protopopov A; Tosello V; Kutok J; Larson RS; Borowitz MJ; Loh ML; Ferrando AA; Winter SS; Mullighan CG; Silverman LB; Chin L; Hunger SP; Sallan SE; Look AT
J Clin Oncol; 2010 Aug; 28(24):3816-23. PubMed ID: 20644084
[TBL] [Abstract][Full Text] [Related]
2. Absence of biallelic TCRγ deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia.
Yang YL; Hsiao CC; Chen HY; Lin KH; Jou ST; Chen JS; Chang TK; Sheen JM; Yu SL; Lu MY; Cheng CN; Wu KH; Wang SC; Wang JD; Chang HH; Lin SR; Lin SW; Lin DT
Pediatr Blood Cancer; 2012 Jun; 58(6):846-51. PubMed ID: 22180181
[TBL] [Abstract][Full Text] [Related]
3. CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol.
Ghazavi F; Clappier E; Lammens T; Suciu S; Caye A; Zegrari S; Bakkus M; Grardel N; Benoit Y; Bertrand Y; Minckes O; Costa V; Ferster A; Mazingue F; Plat G; Plouvier E; Poirée M; Uyttebroeck A; van der Werff-Ten Bosch J; Yakouben K; Helsmoortel H; Meul M; Van Roy N; Philippé J; Speleman F; Cavé H; Van Vlierberghe P; De Moerloose B
Haematologica; 2015 Oct; 100(10):1311-9. PubMed ID: 26137961
[TBL] [Abstract][Full Text] [Related]
4. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
[TBL] [Abstract][Full Text] [Related]
5. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
[TBL] [Abstract][Full Text] [Related]
6. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.
Burns MA; Place AE; Stevenson KE; Gutiérrez A; Forrest S; Pikman Y; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Gennarini LM; Kahn JM; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2021 Jan; 68(1):e28719. PubMed ID: 33026184
[TBL] [Abstract][Full Text] [Related]
7. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
8. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
9. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
Nachman JB; Sather HN; Sensel MG; Trigg ME; Cherlow JM; Lukens JN; Wolff L; Uckun FM; Gaynon PS
N Engl J Med; 1998 Jun; 338(23):1663-71. PubMed ID: 9614257
[TBL] [Abstract][Full Text] [Related]
10. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
[No Abstract] [Full Text] [Related]
11. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
12. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.
Avramis IA; Panosyan EH; Dorey F; Holcenberg JS; Avramis VI;
Clin Cancer Res; 2006 Dec; 12(23):6978-84. PubMed ID: 17145817
[TBL] [Abstract][Full Text] [Related]
13. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.
Oudot C; Auclerc MF; Levy V; Porcher R; Piguet C; Perel Y; Gandemer V; Debre M; Vermylen C; Pautard B; Berger C; Schmitt C; Leblanc T; Cayuela JM; Socie G; Michel G; Leverger G; Baruchel A
J Clin Oncol; 2008 Mar; 26(9):1496-503. PubMed ID: 18349402
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma.
Callens C; Baleydier F; Lengline E; Ben Abdelali R; Petit A; Villarese P; Cieslak A; Minard-Colin V; Rullier A; Moreau A; Baruchel A; Schmitt C; Asnafi V; Bertrand Y; Macintyre E
J Clin Oncol; 2012 Jun; 30(16):1966-73. PubMed ID: 22547598
[TBL] [Abstract][Full Text] [Related]
18. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI
Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021
[TBL] [Abstract][Full Text] [Related]
19. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.
Uckun FM; Yang Z; Sather H; Steinherz P; Nachman J; Bostrom B; Crotty L; Sarquis M; Ek O; Zeren T; Tubergen D; Reaman G; Gaynon P
Blood; 1997 May; 89(10):3769-77. PubMed ID: 9160683
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
